137 related articles for article (PubMed ID: 10227461)
41. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Barlogie B; Kyle RA; Anderson KC; Greipp PR; Lazarus HM; Hurd DD; McCoy J; Moore DF; Dakhil SR; Lanier KS; Chapman RA; Cromer JN; Salmon SE; Durie B; Crowley JC
J Clin Oncol; 2006 Feb; 24(6):929-36. PubMed ID: 16432076
[TBL] [Abstract][Full Text] [Related]
42. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
Le Loët X; Monconduit M; Menard JF; Deshayes P; Grobois B; Tanguy A; Prevost E; Piguet H
Rev Rhum Mal Osteoartic; 1984 May; 51(5):263-7. PubMed ID: 6740189
[TBL] [Abstract][Full Text] [Related]
43. [High dose therapy with autologous stem cell support--finally a progress in myelomatosis].
Wisløff F; Tangen JM; Brinch L; Dahl IM; Gruber FX; Hammerstrøm J; Waage A; Nesthus I; Ernst P
Tidsskr Nor Laegeforen; 2001 Aug; 121(20):2402-6. PubMed ID: 11603051
[TBL] [Abstract][Full Text] [Related]
44. Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol.
Steinke B; Busch FW; Becherer C; Ostendorf P; Waller HD
Cancer Chemother Pharmacol; 1985; 14(3):279-81. PubMed ID: 3838922
[TBL] [Abstract][Full Text] [Related]
45. Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients. Nordic Myeloma Study Group.
Wisløff F; Gulbrandsen N
Acta Oncol; 2000; 39(7):809-13. PubMed ID: 11145438
[TBL] [Abstract][Full Text] [Related]
46. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
Palumbo A; Bringhen S; Rossi D; Cavalli M; Larocca A; Ria R; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Morabito F; Grasso M; Leonardi G; Rizzo M; Falcone AP; Gottardi D; Montefusco V; Musto P; Petrucci MT; Ciccone G; Boccadoro M
J Clin Oncol; 2010 Dec; 28(34):5101-9. PubMed ID: 20940200
[TBL] [Abstract][Full Text] [Related]
47. Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma.
Henon P; Donatini B; Eisenmann JC; Becker M; Beck-Wirth G
Bone Marrow Transplant; 1995 Jul; 16(1):19-25. PubMed ID: 7581122
[TBL] [Abstract][Full Text] [Related]
48. Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma.
Ahre A; Björkholm M; Mellstedt H; Holm G; Brenning G; Engstedt L; Gahrton G; Hällen J; Johansson B; Johansson SG; Karnström L; Killander A; Lerner R; Lockner D; Lönnqvist B; Simonsson B; Stalfelt AM; Ternstedt B; Wadman B
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):499-506. PubMed ID: 6345174
[TBL] [Abstract][Full Text] [Related]
49. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
[TBL] [Abstract][Full Text] [Related]
50. [Therapy of multiple myeloma].
La Verde G; Pulsoni A; Petrucci MT; Mandelli F
Recenti Prog Med; 1997 Apr; 88(4):186-93. PubMed ID: 9206817
[TBL] [Abstract][Full Text] [Related]
51. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Beksac M; Haznedar R; Firatli-Tuglular T; Ozdogu H; Aydogdu I; Konuk N; Sucak G; Kaygusuz I; Karakus S; Kaya E; Ali R; Gulbas Z; Ozet G; Goker H; Undar L
Eur J Haematol; 2011 Jan; 86(1):16-22. PubMed ID: 20942865
[TBL] [Abstract][Full Text] [Related]
52. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
53. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
[TBL] [Abstract][Full Text] [Related]
54. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support.
Gulbrandsen N; Wisløff F; Brinch L; Carlson K; Dahl IM; Gimsing P; Hippe E; Hjorth M; Knudsen LM; Lamvik J; Lenhoff S; Løfvenberg E; Nesthus I; Nielsen JL; Turesson I; Westin J;
Med Oncol; 2001; 18(1):65-77. PubMed ID: 11778972
[TBL] [Abstract][Full Text] [Related]
55. Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central Sweden.
Osterborg A; Ahre A; Björkholm M; Björeman M; Brenning G; Gahrton G; Grimfors G; Gyllenhammar H; Hast R; Johansson B
Acta Oncol; 1990; 29(6):727-31. PubMed ID: 2223143
[TBL] [Abstract][Full Text] [Related]
56. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Fermand JP; Katsahian S; Divine M; Leblond V; Dreyfus F; Macro M; Arnulf B; Royer B; Mariette X; Pertuiset E; Belanger C; Janvier M; Chevret S; Brouet JC; Ravaud P;
J Clin Oncol; 2005 Dec; 23(36):9227-33. PubMed ID: 16275936
[TBL] [Abstract][Full Text] [Related]
57. Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
Barlogie B; Tricot G; Anaissie E; Shaughnessy J; Rasmussen E; van Rhee F; Fassas A; Zangari M; Hollmig K; Pineda-Roman M; Lee C; Talamo G; Thertulien R; Kiwan E; Krishna S; Fox M; Crowley J
N Engl J Med; 2006 Mar; 354(10):1021-30. PubMed ID: 16525139
[TBL] [Abstract][Full Text] [Related]
58. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group.
Wisløff F; Eika S; Hippe E; Hjorth M; Holmberg E; Kaasa S; Palva I; Westin J
Br J Haematol; 1996 Mar; 92(3):604-13. PubMed ID: 8616024
[TBL] [Abstract][Full Text] [Related]
59. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
60. Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.
Osterborg A; Ahre A; Björkholm M; Björeman M; Brenning G; Gahrton G; Gyllenhammar H; Johansson B; Juliusson G; Järnmark M
Eur J Haematol; 1989 Jul; 43(1):54-62. PubMed ID: 2670605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
